On May 15, 2024 CrossBridge Bio, Inc. (CrossBridge), a pioneering pre-clinical stage biotechnology company dedicated to advancing antibody-drug conjugate (ADC) therapeutics for unmet needs through stable dual linker payload technology that aims to significantly improve safety as well as potency/durability while addressing tumor resistance and heterogeneity, proudly announces the receipt of a substantial competitive non-dilutive grant from the Cancer Prevention and Research Institute of Texas (CPRIT) (Press release, CrossBridge Bio, MAY 15, 2024, View Source [SID1234647683]). This grant marks a significant milestone in CrossBridge’s mission to propel its innovative dual-payload ADC platform and potential best-in-class TROP2 program, CBB-120, to IND-enabling studies.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
CrossBridge’s cutting-edge ADC platform is at the forefront of cancer treatment innovation, utilizing site-specific antibody-branched linker conjugation, a stable tripeptide linker, and the ability to conjugate dual payloads via click chemistry. With the non-dilutive grant, CrossBridge is ready to accelerate the pre-clinical development of CBB-120 as a potential differentiated therapeutic for triple-negative breast cancers, hormone-positive Her2-negative breast cancers, and various other TROP2+ cancers with unmet needs, where our dual payloads will be most effective.
"The data we will generate with this grant will support de-risking our next-generation ADC platform and provide another potential option for cancer patients. We are thankful for the review committee and CPRIT for funding CBB-120." CEO and Co-Founder, Michael Torres, Ph.D.
We sincerely thank the Cancer Prevention and Research Institute of Texas (CPRIT) for their support. The $2.6 million seed award highlights CrossBridge’s unwavering commitment to advancing ADC therapeutics and providing transformative treatments to patients with challenging cancers. This funding will boost our pre-clinical efforts and strengthen our position as a trailblazer in ADC innovation.